杭州启明医疗器械股份有限公司 is engaged in the research, development, and industrialization of transcatheter treatment products for structural heart diseases. The company offers a range of structural heart disease solutions, including products for aortic valve, pulmonary valve, mitral, tricuspid valve diseases, and hypertension treatment.

杭州启明医疗器械股份有限公司

心声助手

Euro

CrUX Dataset

Pound Sterling

Japanese Yen

CrUX Top 10m

Market Development Manager Benelux

Job Huiskamp

Sr. R&D and Catheter Technologies Manager

Trinh Pham

Healthcare

Ji Wang

Nisa Leung

Shakeel Osman

Senior VP of Sales Europe to drive commercialization of TPVR system

Zi Zhenjun

Founder & CEO

Health Care Public Companies With More Than 50 Employees

Asia Public Companies With More Than $1M in Revenue (Top 10K)

China Public Companies With More Than 500 Employees

Industrial Public Companies

Venus MedTech (HangZhou) Inc. is located in Hangzhou National High-tech Industrial Development Zone (Binjiang), with its products positioned in the development and industrialization of international advanced interventional artificial cardiac valve system, filling up the blank in China.

Interventional artificial aortic valve products researched and developed by the company takes the lead in finishing clinical tests in China. In reference to the development and promotion conditions of coronary stents at home and abroad, interventional artificial cardiac valve, as a revolutionary treatment means, has been increasingly recognized by experts, and will take on an explosible increase of clinical needs in the foreseeable next few years.

DCP Capital

Private Equity Round - Venus MedTech

Qiming Venture Partners

Series C - Venus MedTech

Goldman Sachs

Series B - Venus MedTech

Venture Round - Venus MedTech

Series A - Venus MedTech

Hangzhou

Zhejiang

China

Asia

Venus MedTech

Venus Medtech Kicks Off PROTEUS IDE Clinical Study in U.S.

Venus Medtech touts first implants of transcatheter pulmonic valve replacement system

Venus Medtech VenusP-Valve transcatheter pulmonic valve replacement system granted Health Canada approval

Venus Medtech VenusP-Valve Completed First Implantation in IDE Pivotal Clinical Study in U.S.

Holder, packaging box, and packaging system for prosthetic valve

Prosthetic heart valve stent for atrioventricular valve, interventional device, …

Health Canada approves Venus Medtech's TPVR system

Switzerland

Europe

United States

North America

Russian Federation

Taiwan

Spain

Venus Medtech (Hangzhou) Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company's products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of brain damage and prevent cerebral embolism during TAVR and other structural heart disease surgeries. It also develops VenusA-Plus and VenusA-Pilot, which are TAVR product candidates; and transcatheter mitral and tricuspid valve replacement products; Liwen RF ablation system for the treatment of hypertrophic cardiomyopathy; and renal denervation for the treatment of hypertension. The company was founded in 2009 and is headquartered in Hangzhou, the People's Republic of China.

Venus Medtech (Hangzhou) Inc.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 27, 2024 4:58 PM	2cf4c8f0
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Sep 27, 2024 4:58 PM	6aa87522
crunchbase trigger	general	Dec 4, 2024 8:54 AM	cb8992ef
crunchbase profile	general	Dec 4, 2024 9:29 AM	54fb64f5
li profile	general
translate crunchbase fundingrounds	general	Dec 4, 2024 10:27 AM	9c2ca0f7
peers	general	Sep 27, 2024 4:58 PM	251916d9
news basic	general	Sep 27, 2024 4:58 PM	65e74c78
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:VENUSMEDTECH

杭州启明医疗器械股份有限公司

Last Close

5.62

23/07 20:00

Market Cap

2.46B

Beta: -

Volume Today

6.42M

Avg: -